Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial

• Hoofdauteurs: Chao Deng (Auteur), Qing Liu (Auteur), Meng Yang (Auteur), Hui-juan Cui (Auteur), Yang Ge (Auteur), Qin Li (Auteur), Shi-jie Zhu (Auteur), Guo-wang Yang (Auteur), Zhi-guo Zhang (Auteur), Yu Gao (Auteur), Yan-ni Lou (Auteur), Li-qun Jia (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2024-11-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We...